Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial

References

• Dempster DW, Shane E, Horbert W, Lindsay R. A simple method for correlative light and scanning electron microscopy of human iliac crest bone biopsies: qualitative observations in normal and osteoporotic subjects. J Bone Miner Res 1986;1:15–21
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23
   PubMed Web of Science ®Google Scholar
• Melton LJ 3d, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72–5
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. . Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–3
   PubMed Web of Science ®Google Scholar
• Jacobs S, Hillard TC. Hormone replacement therapy in the aged: a state of the art review. Drugs Aging 1996;3:193–213
   Google Scholar
• Reid IR. Pharmacological management of osteo-porosis in postmenopausal women: a comparativereview.DrugsAging1999;15:349–63
   Google Scholar
• Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas 1998;31:45–54
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal wo-men: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al., for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomizedcontrolledtrial.JAMA2003;289:2651–62
   Google Scholar
• Hays J, Ockene JK, Brunner RL, et al., Women's Health Initiative Investigators. Effects of estro-gen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839–54
   Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al., for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replace-ment Study follow-up (HERS II). JAMA 2002;288: 58–66
   Google Scholar
• Grady D, Herrington D, Bittner V, et al., for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 49–57
   Google Scholar
• Grady D. Postmenopausal hormones — therapy for symptoms only. N Engl J Med 2003;348:1835–7
   PubMed Web of Science ®Google Scholar
• Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161:1854–8
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteo-porosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747–54
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282: 637–45
   Google Scholar
• Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337–44
   PubMed Web of Science ®Google Scholar
• Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998;12:335–41
   PubMed Web of Science ®Google Scholar
• Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. 0 bstet Gynecol 1999;93: 558–65
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al., for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral frac-tures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344–52
   Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91
   Google Scholar
• Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate rise-dronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955–62
   PubMed Web of Science ®Google Scholar
• Mortensen L, Charles P, Bekker PJ, DiGennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endo crinol Metab 1998;83:396–402
   Google Scholar
• Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485–92
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R. Prevention of early postmenopausal bone loss with cyclical etidro-nate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997;82:2784–91
   PubMed Web of Science ®Google Scholar
• Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I. The prevention of early postmeno- pausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 1997;103: 92–9
   Google Scholar
• McClung M, Clemmesen B, Daifotis A, et al., for the Alendronate Osteoporosis Prevention Study Group. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med 1998;128:253–61
   Google Scholar
• Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277–85
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al., for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–40
   Google Scholar
• Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Colina RE, Smith M, Kikendall JW, Wong RK. A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol 1997;92:704–6
   PubMed Web of Science ®Google Scholar
• de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendro-nate. N Engl J Med 1996;335:1016–21
   PubMed Web of Science ®Google Scholar
• Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastro-enterol 1995;90:1889–90
   Web of Science ®Google Scholar
• Faulkner KG, McClung MR. Quality control of DXA instruments in multicenter trials. Osteo-poros Int 1995;5:218–27
   PubMed Web of Science ®Google Scholar
• Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorp-tiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503–14
   PubMed Web of Science ®Google Scholar
• Steiger P. Standardization of postero-anterior (PA) spine BMD measurements by DXA. Com-mittee for Standards in DXA. Bone 1995;17:435
   Google Scholar
• National Osteoporosis Foundation Working Group on Vertebral Fractures. Assessing verteb-ral fractures. J Bone Miner Res 1995;10:518–23
   PubMed Web of Science ®Google Scholar
• Armitage P. Tests for linear trends in propor-tions and frequencies. Biometrics 1955;11:375–86
   Web of Science ®Google Scholar
• Genant HK, Lucas J, Weiss S, et al., for the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med 1997;157:2609–15
   Google Scholar
• Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteo-porosis Treatment Study Group. N Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two rando-mized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717–26
   PubMed Web of Science ®Google Scholar
• Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedro-nate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77:262–70
   PubMed Web of Science ®Google Scholar